Abstract 101P
Background
Blood vascular angiosarcoma is an uncommon and aggressive malignancy that has responded well to several combinations of immunotherapy. Conventional medicines like radiation and chemotherapy are not very successful, however immunotherapies such bempegaldesleukin + nivolumab, epacadostat + pembrolizumab, and Immune checkpoint inhibitors (ICIs) have shown positive outcomes in certain individuals. Ipilimumab + nivolumab and pembrolizumab, have also demonstrated promise in slowing the course of the illness and raising survival rates.
Methods
This study was conducted based on PRISMA reporting guidelines. All included studies were derived from PubMed, Sciencedirect, NEJM, and Europe PMC databases using a set of keywords: Angiosarcoma, Pembrolizumab, and Immunotherapies. Studies were extracted and evaluated based on inclusion (Accessible full text, Randomized Controlled Trial, Clinical Trials, and last 5 years) and exclusion criterias (non-english text, animal studies, case report, systematic reviews, and meta analysis) The quality of included studies were further assessed using Newcastle-Ottawa Scale (NOS).
Results
Seven studies consisting of RCTs and clinical trials were included, screening a total of 195 patients. Among the seven studies, bempegaldesleukin + nivolumab yields 0.60 (95% Cl; 0.08-4.40; P < 0.00001), epacadostat + pembrolizumab yields 0.03 (95% Cl; 0.00-0.29; P < 0.00001), ipilimumab + nivolumab yields 0.33 (95% Cl; 0.07-1.49; P < 0.00001), pembrolizumab alone yields 3.33 (95% Cl; 0.36-30.70; P < 0.00001), and Immune checkpoint inhibitors (ICIs) yields 0.13 (95% Cl; 0.02-0.71; P < 0.00001) Adverse effect wise is 17.00 (95% Cl; 0.74-391.68; P < 0.00001), 0.30 (95% Cl; 0.10-0.92; P < 0.00001), 3.00 (95% Cl; 0.67-13.40; P < 0.00001), 0.09 (95% Cl; 0.00-2.07; P < 0.00001), and 5.00 (95% Cl; 1.07-23.46; P < 0.00001), respectively.
Conclusions
This research shows that monotherapy drugs, pembrolizumab alone, are better than other combinations and ICIs in terms of ORR and adverse effect.
Legal entity responsible for the study
Enzo Marson.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
195P - Anti-CTLA4 therapy leads to early expansion of peripheral Th17 population and induction of Th1 cytokines
Presenter: Mari Nakazawa
Session: Poster Display session
Resources:
Abstract
196P - Single-cell analysis of stage-I high-grade serous ovarian carcinoma reveals the essential role of regulatory T cells in early tumor establishment
Presenter: Joanna Mikulak
Session: Poster Display session
Resources:
Abstract
197P - Comprehensive immunoprofiling of the intratumoral and peripheral T cell receptor gene repertoire in triple-negative breast cancer patients
Presenter: Antonios Mingos
Session: Poster Display session
Resources:
Abstract
198P - Association of types of treatment modalities with expression of T Lymphocytes (CD4, CD8, Treg) in breast cancer patients and their clinical outcome
Presenter: Arshi Rizwan
Session: Poster Display session
Resources:
Abstract
199P - Cancer neutrophil encyclopedia: A deep dive into antigen-presenting warriors
Presenter: Yingcheng Wu
Session: Poster Display session
Resources:
Abstract
200P - CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant NSCLC
Presenter: Haowei Wang
Session: Poster Display session
Resources:
Abstract
201P - Underlying mechanisms of neutrophil-mediated immunosuppression and resistance to treatment in breast cancer: Further evidence that these cells matter
Presenter: Bruna Filipa Correia
Session: Poster Display session
Resources:
Abstract
202P - Mining tumor infiltrating B cells to discover antibody-target pairs and develop novel therapies
Presenter: Matthieu Delince
Session: Poster Display session
Resources:
Abstract
203P - Targeting IL-33 reprograms tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy
Presenter: Xuyao Zhang
Session: Poster Display session
Resources:
Abstract
204P - Deciphering the crosstalk between tumor and circulating immune microenvironment in advanced NSCLC patients undergoing immunotherapy
Presenter: Prisca Tamarozzi
Session: Poster Display session
Resources:
Abstract